AbbVie In Hot Seat Over HCV Drugs' Serious Liver Injury Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
After adverse event reports in patients with underlying advanced liver damage, FDA requires AbbVie to add risk language to Viekira Pak and Technivie labels. AbbVie may not see much long-term damage, but Merck likely will gain more traction when it enters the hepatitis C market.
You may also be interested in...
Direct-Acting Antivirals Slapped With Black Box On Hepatitis B Risk
FDA imposes boxed warning on labels for hepatitis C drugs in response to reports of hepatitis B reactivation, including fatal cases.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.